FDA Panel Votes Against Broad Talazoparib-Enzalutamide Label in Prostate Cancer

Source link : https://newshealth.biz/health-news/fda-panel-votes-against-broad-talazoparib-enzalutamide-label-in-prostate-cancer/

(MedPage Today) — An FDA advisory committee on Wednesday unanimously voted against recommending approval of the PARP inhibitor talazoparib (Talzenna) plus enzalutamide (Xtandi) for all patients with metastatic castration-resistant prostate cancer… Source link : https://www.medpagetoday.com/hematologyoncology/prostatecancer/115713 Author : Publish date : 2025-05-22 13:41:00 Copyright for syndicated content belongs to the linked Source.

The post FDA Panel Votes Against Broad Talazoparib-Enzalutamide Label in Prostate Cancer first appeared on News Health.

—-

Author : News Health

Publish date : 2025-05-22 13:41:00

Copyright for syndicated content belongs to the linked Source.

—-

1 – 2 – 3 – 4 – 5 – 6 – 7 – 8